Behavioral Disorders Drug Development Pipeline Review, 2017

  • ID: 4410322
  • Report
  • Region: Global
  • 113 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Alcobra Ltd
  • BioHealthonomics Inc
  • F. Hoffmann-La Roche Ltd
  • KemPharm Inc
  • NeuroDerm Ltd
  • MORE

Summary

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. There are a total of 41 products in development for this indication, by 34 companies and 4 academic institutions. Key companies operating in this pipeline space include Addex Therapeutics, Confluence Pharmaceuticals and Immuron.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. There are a total of 8 products in development for this indication by 7 companies. Key companies operating in this pipeline space include Addex Therapeutics, Abbvie, Omeros and Phytecs.

Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 58 products in development for this indication, by 41 companies and 5 academic institutions. Key companies operating in this pipeline space include NLS Pharma, Aevi Genomic Medicine, Shire and Highland Therapeutics.

Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for behavioral disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • Alcobra Ltd
  • BioHealthonomics Inc
  • F. Hoffmann-La Roche Ltd
  • KemPharm Inc
  • NeuroDerm Ltd
  • MORE

1 Table of Contents

2 Introduction
2.1 Behavioral Disorders Report Coverage
2.2 Autism - Overview
2.3 Obsessive-Compulsive Disorder - Overview
2.4 Attention Deficit Hyperactivity Disorder (ADHD) - Overview

3 Therapeutics Development
3.1 Autism
3.2 Obsessive-Compulsive Disorder
3.3 Attention Deficit Hyperactivity Disorder (ADHD)

4 Therapeutics Assessment
4.1 Autism
4.2 Obsessive-Compulsive Disorder
4.3 Attention Deficit Hyperactivity Disorder (ADHD)

5 Companies Involved in Therapeutics Development
5.1 Autism
5.2 Obsessive-Compulsive Disorder
5.3 Attention Deficit Hyperactivity Disorder (ADHD)

6 Dormant Projects
6.1 Autism
6.2 Obsessive-Compulsive Disorder
6.3 Attention Deficit Hyperactivity Disorder (ADHD)

7 Discontinued Products
7.1 Autism
7.2 Obsessive-Compulsive Disorder
7.3 Attention Deficit Hyperactivity Disorder (ADHD)

8 Product Development Milestones
8.1 Autism
8.2 Obsessive-Compulsive Disorder
8.3 Attention Deficit Hyperactivity Disorder (ADHD)

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Autism
Table 2: Number of Products under Development by Companies, Autism
Table 3: Number of Products under Development by Universities/Institutes, Autism
Table 4: Products under Development by Companies, Autism
Table 5: Products under Development by Universities/Institutes, Autism
Table 6: Number of Products under Development for Obsessive-Compulsive Disorder
Table 7: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
Table 8: Products under Development by Companies, Obsessive-Compulsive Disorder
Table 9: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
Table 10: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
Table 11: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
Table 12: Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
Table 13: Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
Table 14: Number of Products by Stage and Target, Autism
Table 15: Number of Products by Stage and Mechanism of Action, Autism
Table 16: Number of Products by Stage and Route of Administration, Autism
Table 17: Number of Products by Stage and Molecule Type, Autism
Table 18: Number of Products by Stage and Target, Obsessive-Compulsive Disorder
Table 19: Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder
Table 20: Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder
Table 21: Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder
Table 22: Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD)
Table 23: Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD)
Table 24: Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
Table 25: Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD)
Table 26: Autism - Pipeline by 4D Pharma PLC
Table 27: Autism - Pipeline by Addex Therapeutics Ltd
Table 28: Autism - Pipeline by Aequus Pharmaceuticals Inc
Table 29: Autism - Pipeline by Aevi Genomic Medicine Inc
Table 30: Autism - Pipeline by AgeneBio Inc
Table 31: Autism - Pipeline by Anima Biotech Ltd
Table 32: Autism - Pipeline by APeT Holding BV
Table 33: Autism - Pipeline by BioCrea GmbH
Table 34: Autism - Pipeline by BioHealthonomics Inc
Table 35: Autism - Pipeline by BrainStorm Cell Therapeutics Inc
Table 36: Autism - Pipeline by Confluence Pharmaceuticals LLC
Table 37: Autism - Pipeline by Coronis NeuroSciences Ltd
Table 38: Autism - Pipeline by Curemark LLC
Table 39: Autism - Pipeline by DRI Biosciences Corp
Table 40: Autism - Pipeline by F. Hoffmann-La Roche Ltd
Table 41: Autism - Pipeline by GW Pharmaceuticals Plc
Table 42: Autism - Pipeline by Heptares Therapeutics Ltd
Table 43: Autism - Pipeline by Immuron Ltd
Table 44: Autism - Pipeline by Intra-Cellular Therapies Inc
Table 45: Autism - Pipeline by Leading BioSciences Inc
Table 46: Autism - Pipeline by MedDay SA
Table 47: Autism - Pipeline by Omeros Corp
Table 48: Autism - Pipeline by OptiNose US Inc
Table 49: Autism - Pipeline by Ovensa Inc
Table 50: Autism - Pipeline by Q BioMed Inc
Table 51: Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd
Table 52: Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc
Table 53: Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd
Table 54: Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc
Table 55: Obsessive-Compulsive Disorder - Pipeline by Omeros Corp
Table 56: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS
Table 57: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc
Table 58: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd
Table 59: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc
Table 60: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV
Table 61: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd
Table 62: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc
Table 63: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC
Table 64: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc
Table 65: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC
Table 66: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp
Table 67: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company
Table 68: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S
Table 69: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd
Table 70: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc
Table 71: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc
Table 72: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc
Table 73: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc
Table 74: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc
Table 75: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd
Table 76: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG
Table 77: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc
Table 78: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd
Table 79: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience
Table 80: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc
Table 81: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc
Table 82: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd
Table 83: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc
Table 84: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc
Table 85: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
Table 86: Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc
Table 87: Autism - Dormant Projects
Table 88: Obsessive-Compulsive Disorder - Dormant Projects
Table 89: Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Table 90: Autism - Discontinued Products
Table 91: Obsessive-Compulsive Disorder - Discontinued Products
Table 92: Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products

List of Figures
Figure 1: Number of Products under Development for Autism
Figure 2: Number of Products under Development by Companies, Autism
Figure 3: Number of Products under Development by Universities/Institutes, Autism
Figure 4: Number of Products under Development for Obsessive-Compulsive Disorder
Figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
Figure 6: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
Figure 7: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 8: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 9: Number of Products by Top 10 Targets, Autism
Figure 10: Number of Products by Stage and Top 10 Targets, Autism
Figure 11: Number of Products by Top 10 Mechanism of Actions, Autism
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Autism
Figure 13: Number of Products by Routes of Administration, Autism
Figure 14: Number of Products by Stage and Routes of Administration, Autism
Figure 15: Number of Products by Molecule Types, Autism
Figure 16: Number of Products by Stage and Molecule Types, Autism
Figure 17: Number of Products by Targets, Obsessive-Compulsive Disorder
Figure 18: Number of Products by Stage and Targets, Obsessive-Compulsive Disorder
Figure 19: Number of Products by Mechanism of Actions, Obsessive-Compulsive Disorder
Figure 20: Number of Products by Stage and Mechanism of Actions, Obsessive-Compulsive Disorder
Figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder
Figure 22: Number of Products by Stage and Molecule Types, Obsessive-Compulsive Disorder
Figure 23: Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 24: Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 25: Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 27: Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 28: Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 29: Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
Figure 30: Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4D Pharma PLC
  • 4P-Pharma SAS
  • APeT Holding BV
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • Aevi Genomic Medicine Inc
  • AgeneBio Inc
  • Alcobra Ltd
  • Amarantus Bioscience Holdings Inc
  • Amorsa Therapeutics Inc
  • Anima Biotech Ltd
  • BCWorld Pharm Co Ltd
  • BioCrea GmbH
  • BioHealthonomics Inc
  • BrainStorm Cell Therapeutics Inc
  • Cingulate Therapeutics LLC
  • Collegium Pharmaceutical Inc
  • Confluence Pharmaceuticals LLC
  • Coronis NeuroSciences Ltd
  • Curemark LLC
  • DRI Biosciences Corp
  • DURECT Corp
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Heptares Therapeutics Ltd
  • Highland Therapeutics Inc
  • Immuron Ltd
  • Intra-Cellular Therapies Inc
  • KemPharm Inc
  • Leading BioSciences Inc
  • Luc Therapeutics Inc
  • MedDay SA
  • Merck & Co Inc
  • Neos Therapeutics Inc
  • NeuroDerm Ltd
  • Novartis AG
  • Noven Pharmaceuticals Inc
  • Omeros Corp
  • OptiNose US Inc
  • Otsuka Pharmaceutical Co Ltd
  • Ovensa Inc
  • P2D Bioscience
  • Q BioMed Inc
  • Reviva Pharmaceuticals Inc
  • SK Biopharmaceuticals Co Ltd
  • Shire Plc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunovion Pharmaceuticals Inc
  • Supernus Pharmaceuticals Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Tris Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll